Companion diagnostics as an integral part of personalised medicine

More and more drugs as well as therapeutic areas are becoming subjects for companion diagnostic test development. Recent FDA approvals of melanoma drug Zelboraf along with BRAF mutation test, and lung cancer drug Xalkori along with ALK gene test have boosted both enthusiasm and investment in drug-diagnostic co-development. The fourth annual Companion Diagnostics conference will present the point of view of all the stakeholders involved in the process of companion diagnostic test design, manufacturing and clinical implementation. Case studies of successful collaboration between pharmaceutical and diagnostics companies’ researchers will be presented.